Bristol, needing a cancer immunotherapy boost, pays shockingly steep price for Nektar drug – STAT
STAT |
Bristol, needing a cancer immunotherapy boost, pays shockingly steep price for Nektar drug
STAT ristol-Myers Squibb, seeking a new way to make its cancer immunotherapies more effective, is paying a shockingly steep — some will say desperate — price to lock up rights to an experimental drug from Nektar Therapeutics. Under deal terms announced … Bristol-Myers Bets Nearly $2B on Nektar for an Immunotherapy Boost Record-smashing $3.6 billion deal propels SF drug company in cancer immunotherapy pack Pay Your Money and Hold Your Breath |
